Edition:
United Kingdom

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

7.95USD
18 May 2018
Change (% chg)

$-0.15 (-1.85%)
Prev Close
$8.10
Open
$8.15
Day's High
$8.25
Day's Low
$7.80
Volume
70,814
Avg. Vol
119,487
52-wk High
$14.00
52-wk Low
$5.85

Select another date:

Wed, May 2 2018

BRIEF-Aduro Biotech Q1 Loss Per Share $0.28

* Q1 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Aduro Announces Milestone Achieved Under Merck Collaboration

* ADURO ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF ANTI-CD27 PHASE I TRIAL IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Promotes Hans Van Eenennaam In Its Europe Unit

* ADURO BIOTECH APPOINTS HANS VAN EENENNAAM EXECUTIVE VICE PRESIDENT ANTIBODY RESEARCH AND SITE HEAD, ADURO BIOTECH EUROPE Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Q4 Loss Per Share $0.34

* ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER

BRIEF-Aduro Biotech Expands Leading Intellectual Property Position In STING Field With Newly Issued Patent

* ADURO BIOTECH EXPANDS LEADING INTELLECTUAL PROPERTY POSITION IN STING FIELD WITH NEWLY ISSUED PATENT Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

Select another date: